Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-activated donor lymphocyte infusion
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
DC-activated donor lymphocyte infusion (DC/ADL) is an experimental adoptive cellular immunotherapy developed by the M.D. Anderson Cancer Center. This personalized therapy is designed for patients with relapsed acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) in blast crisis following an allogeneic stem cell transplantation. The therapeutic process involves the ex vivo generation of dendritic cells from the patient's own leukemic blasts, which are then used to prime and activate allogeneic donor lymphocytes. These activated donor T-cells are infused back into the patient to enhance the graft-versus-leukemia (GVL) effect. By specifically targeting leukemia-associated antigens presented by the dendritic cells, the therapy aims to stimulate a potent anti-leukemic immune response while attempting to minimize the risk of systemic graft-versus-host disease (GVHD).
- Other names
- Anti-Leukemic Dendritic Cell Activated Donor LymphocytesDC-Activated Donor LymphocytesDendritic Cell-Activated Donor Lymphocyte Infusion
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on DC-activated donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-activated donor lymphocyte infusion.